Bayer and Regeneron report positive results for VEGF Trap-Eye in central retinal vein occlusion and in diabetic macular edema

Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO). End Quote

(1888PressRelease) December 23, 2010 - In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at least 15 letters of vision from baseline, compared to 12.3 percent of patients receiving sham injections (p

###

space

Other Related Press Releases

Genzyme details market potential of Alemtuzumab for MS by Economic News
Bayer and Regeneron report positive results for VEGF Trap-Eye in central retinal vein occlusion and in diabetic macular edema by Business Updates
Foster Wheeler awarded contract for new blending plant in Belgium by Kuwait Petroleum International Lubricants by Business Updates